JP2021063129A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021063129A5 JP2021063129A5 JP2021003152A JP2021003152A JP2021063129A5 JP 2021063129 A5 JP2021063129 A5 JP 2021063129A5 JP 2021003152 A JP2021003152 A JP 2021003152A JP 2021003152 A JP2021003152 A JP 2021003152A JP 2021063129 A5 JP2021063129 A5 JP 2021063129A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- seq
- antibody
- constant region
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023110414A JP7605914B2 (ja) | 2015-07-14 | 2023-07-05 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2024217195A JP2025038055A (ja) | 2015-07-14 | 2024-12-12 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562192269P | 2015-07-14 | 2015-07-14 | |
| US62/192,269 | 2015-07-14 | ||
| US201562197966P | 2015-07-28 | 2015-07-28 | |
| US62/197,966 | 2015-07-28 | ||
| US201662277201P | 2016-01-11 | 2016-01-11 | |
| US62/277,201 | 2016-01-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521475A Division JP6826113B2 (ja) | 2015-07-14 | 2016-07-13 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023110414A Division JP7605914B2 (ja) | 2015-07-14 | 2023-07-05 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021063129A JP2021063129A (ja) | 2021-04-22 |
| JP2021063129A5 true JP2021063129A5 (https=) | 2021-06-10 |
Family
ID=57757587
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521475A Active JP6826113B2 (ja) | 2015-07-14 | 2016-07-13 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2021003152A Pending JP2021063129A (ja) | 2015-07-14 | 2021-01-13 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2023110414A Active JP7605914B2 (ja) | 2015-07-14 | 2023-07-05 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2024217195A Pending JP2025038055A (ja) | 2015-07-14 | 2024-12-12 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521475A Active JP6826113B2 (ja) | 2015-07-14 | 2016-07-13 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023110414A Active JP7605914B2 (ja) | 2015-07-14 | 2023-07-05 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2024217195A Pending JP2025038055A (ja) | 2015-07-14 | 2024-12-12 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10874738B2 (https=) |
| EP (2) | EP3331548B1 (https=) |
| JP (4) | JP6826113B2 (https=) |
| KR (2) | KR20250099272A (https=) |
| CN (2) | CN108135969B (https=) |
| AU (3) | AU2016294417B2 (https=) |
| CL (1) | CL2018000103A1 (https=) |
| CO (1) | CO2018001363A2 (https=) |
| CR (1) | CR20180097A (https=) |
| DO (1) | DOP2018000018A (https=) |
| EA (1) | EA201890297A1 (https=) |
| EC (1) | ECSP18009949A (https=) |
| GT (1) | GT201800018A (https=) |
| HK (1) | HK1249735A1 (https=) |
| IL (3) | IL256800B2 (https=) |
| MX (2) | MX2018000548A (https=) |
| MY (2) | MY196991A (https=) |
| PE (1) | PE20180741A1 (https=) |
| PH (1) | PH12018500098A1 (https=) |
| SG (1) | SG10201913431QA (https=) |
| TN (1) | TN2018000021A1 (https=) |
| WO (1) | WO2017011544A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180097A (es) * | 2015-07-14 | 2018-05-25 | Immunext Inc | Anticuerpo anti-cd154 con caracteristicas de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana |
| KR20180080337A (ko) | 2015-11-27 | 2018-07-11 | 아블린쓰 엔.브이. | Ｃｄ40ｌ을 억제하는 폴리펩티드 |
| AU2019247511B2 (en) | 2018-04-06 | 2025-10-16 | Atyr Pharma, Inc. | Compositions and methods comprising anti-NRP2 antibodies |
| WO2020056162A1 (en) * | 2018-09-12 | 2020-03-19 | Oregon Health & Science University | Detecting and/or subtyping circulating hybrid cells that correlate with stage and survival |
| US20210317220A1 (en) * | 2018-09-24 | 2021-10-14 | Janssen Biotech, Inc. | Method of providing safe administration of an anti-cd154 antibody |
| CN115227824A (zh) * | 2018-11-12 | 2022-10-25 | 中南大学湘雅二医院 | 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用 |
| WO2020210831A1 (en) * | 2019-04-12 | 2020-10-15 | TONIX Pharmaceuticals Holding Corp | Inhibitors of cd40-cd154 binding |
| CA3156803A1 (en) * | 2019-10-03 | 2021-04-08 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
| CN113488170B (zh) * | 2021-07-02 | 2023-07-25 | 温州医科大学 | 急性前葡萄膜炎复发风险预测模型构建方法及相关设备 |
| KR20230019798A (ko) * | 2021-07-30 | 2023-02-09 | 서울대학교산학협력단 | 항 cd154 항체 및 이의 용도 |
| WO2023008982A1 (ko) * | 2021-07-30 | 2023-02-02 | 서울대학교산학협력단 | 항 cd154 항체 및 이의 용도 |
| WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
| WO2024222895A1 (zh) | 2023-04-28 | 2024-10-31 | 信达生物制药(苏州)有限公司 | 抗cd40l抗体及其在人自身免疫疾病治疗的应用 |
| US20240392022A1 (en) | 2023-05-22 | 2024-11-28 | Genzyme Corporation | Treatment of multiple sclerosis with anti-cd40l antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2143553T3 (es) | 1993-09-02 | 2000-05-16 | Dartmouth College | Anticuerpos anti-gp39 y sus utilizaciones. |
| US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6444018B1 (en) | 1998-06-25 | 2002-09-03 | Xerox Corporation | Phase change ink carrier compositions containing anhydride/amino alcohol-based adducts |
| GB0006398D0 (en) | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| PL366307A1 (en) | 2000-10-13 | 2005-01-24 | Biogen, Inc. | Humanized anti-lt-beta-r antibodies |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| EP1639014B1 (en) | 2003-06-13 | 2010-09-22 | Biogen Idec MA Inc. | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| US20110123440A1 (en) | 2005-03-29 | 2011-05-26 | Genevieve Hansen | Altered Antibody FC Regions and Uses Thereof |
| ME00832B (me) * | 2007-03-22 | 2012-03-20 | Ucb Biopharma Sprl | Vezivni proteini uključujući antitjela, derivate antitjela i fragmente antitjela, koji specifično vezuju cd154 i njihova upotreba |
| US9321833B2 (en) * | 2011-04-04 | 2016-04-26 | The Trustees Of Dartmouth College | Methods of therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
| CA2832281C (en) * | 2011-04-04 | 2019-11-05 | Trustees Of Dartmouth College | Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies |
| CR20180097A (es) * | 2015-07-14 | 2018-05-25 | Immunext Inc | Anticuerpo anti-cd154 con caracteristicas de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana |
-
2016
- 2016-07-13 CR CR20180097A patent/CR20180097A/es unknown
- 2016-07-13 MX MX2018000548A patent/MX2018000548A/es unknown
- 2016-07-13 WO PCT/US2016/042074 patent/WO2017011544A1/en not_active Ceased
- 2016-07-13 EP EP16825103.1A patent/EP3331548B1/en active Active
- 2016-07-13 MY MYPI2018700104A patent/MY196991A/en unknown
- 2016-07-13 IL IL256800A patent/IL256800B2/en unknown
- 2016-07-13 PE PE2018000072A patent/PE20180741A1/es unknown
- 2016-07-13 HK HK18109202.5A patent/HK1249735A1/zh unknown
- 2016-07-13 KR KR1020257020732A patent/KR20250099272A/ko active Pending
- 2016-07-13 TN TNP/2018/000021A patent/TN2018000021A1/en unknown
- 2016-07-13 IL IL297907A patent/IL297907B2/en unknown
- 2016-07-13 EA EA201890297A patent/EA201890297A1/ru unknown
- 2016-07-13 IL IL310460A patent/IL310460A/en unknown
- 2016-07-13 SG SG10201913431QA patent/SG10201913431QA/en unknown
- 2016-07-13 KR KR1020187004571A patent/KR102825142B1/ko active Active
- 2016-07-13 EP EP26164394.4A patent/EP4732909A2/en active Pending
- 2016-07-13 JP JP2018521475A patent/JP6826113B2/ja active Active
- 2016-07-13 CN CN201680053004.3A patent/CN108135969B/zh active Active
- 2016-07-13 CN CN202210146798.5A patent/CN114671952A/zh active Pending
- 2016-07-13 US US15/744,379 patent/US10874738B2/en active Active
- 2016-07-13 AU AU2016294417A patent/AU2016294417B2/en active Active
- 2016-07-13 MY MYPI2020006781A patent/MY203911A/en unknown
-
2018
- 2018-01-11 PH PH12018500098A patent/PH12018500098A1/en unknown
- 2018-01-12 GT GT201800018A patent/GT201800018A/es unknown
- 2018-01-12 MX MX2023014921A patent/MX2023014921A/es unknown
- 2018-01-12 DO DO2018000018A patent/DOP2018000018A/es unknown
- 2018-01-12 CL CL2018000103A patent/CL2018000103A1/es unknown
- 2018-02-09 EC ECIEPI20189949A patent/ECSP18009949A/es unknown
- 2018-02-12 CO CONC2018/0001363A patent/CO2018001363A2/es unknown
-
2020
- 2020-11-23 US US17/101,139 patent/US11596689B2/en active Active
-
2021
- 2021-01-13 JP JP2021003152A patent/JP2021063129A/ja active Pending
-
2022
- 2022-11-02 AU AU2022263520A patent/AU2022263520B2/en active Active
-
2023
- 2023-02-01 US US18/162,769 patent/US20240000929A1/en active Pending
- 2023-07-05 JP JP2023110414A patent/JP7605914B2/ja active Active
-
2024
- 2024-12-12 JP JP2024217195A patent/JP2025038055A/ja active Pending
-
2025
- 2025-09-05 AU AU2025226796A patent/AU2025226796A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021063129A5 (https=) | ||
| US12116405B2 (en) | Arthritis treatment | |
| JP6096938B2 (ja) | Ｉｌ−２３を結合する抗体 | |
| TWI713453B (zh) | 干擾素α及ω抗體拮抗劑 | |
| CN101512008A (zh) | 白介素-13结合蛋白 | |
| TW202206462A (zh) | 具有經修飾重鏈恆定區之多特異性重鏈抗體 | |
| JP2019525730A (ja) | 抗ヒトインターロイキン−１７ａモノクローナル抗体、その製造方法及び用途 | |
| TW201030016A (en) | Antibodies that bind to IL-18 and methods of purifying the same | |
| JP2023505492A5 (https=) | ||
| JP7783183B2 (ja) | 自己免疫障害における抗ｂｃｍａ治療 | |
| CN105358575B (zh) | 干扰素α和ω抗体拮抗剂 | |
| CN110662768A (zh) | 治疗性抗cd40配体抗体 | |
| TW201233395A (en) | Methods for treating psoriasis | |
| US20060188505A1 (en) | Treatment of autism | |
| US20230159632A1 (en) | Anti-il-17a antibody and use thereof | |
| WO2004004765A1 (en) | Treatment of autoimmune skin diseases | |
| TW202114734A (zh) | Il-17拮抗劑治療自身免疫疾病的方法 | |
| EA050324B1 (ru) | Терапия антителами против bcma при аутоиммунных расстройствах | |
| AU2017200039B2 (en) | Arthritis treatment | |
| BR122025021892A2 (pt) | Células hospedeiras |